ABSTRACT BACKGROUND The HeartMate 3 left ventricular assist system (LVAS) is intended to provide long-term support to
. Gastrointestinal bleeding has emerged as an adverse event in patients with continuous-flow LVAS support (6) (7) (8) , whereas right HF, infection, stroke, and pump thrombosis continue to be complications associated with significant morbidity and mortality (9) (10) (11) (12) . Given that patients will present for durable LVAS support with comorbid conditions, and many will require such support for long durations, technological enhancements that address hemocompatibility may help reduce the frequency and severity of these adverse events.
Contemporary axial-flow and centrifugal-flow
LVASs pump blood through narrow flow pathways, which contributes to hemolysis, platelet activation, and damage to von Willebrand factor (vWF) (13) (14) (15) (16) (17) . The HeartMate 3 LVAS (St. Jude Medical, Pleasanton, California) is a new, miniaturized centrifugal-flow device designed to enhance hemocompatibility by minimizing shear force effects on blood components and by incorporating an optimized blood-biomaterial interface (18) .
Additionally, an artificial pulse may help avoid blood stasis within the left ventricle (LV), allowing the aortic valve to function. These features may potentially limit the major contributing factors to hemorrhagic, thrombotic, and infectious complications.
The purpose of this study was to evaluate the performance and safety of this fully magnetically levitated LVAS in patients with advanced HF. We present the primary endpoint analysis and 6-month results from this study conducted to meet Conformité Européenne (CE) mark requirements. INTERMACS adverse event definitions were used in this study (20) . Adults with an ejection fraction #25%, Netuka et al.
METHODS
with ongoing support at 6 months will be followed for Table 2) .
OUTCOMES. The 30-day and 6-month survival were 98% and 92%, respectively. The lower 97.5% confidence limit for survival was 83%, which is within 5% of the performance goal of 88%, thus the primary endpoint as specified in the study was met. The SHFM Table 3 . Table 4 ; the majority occurred within 30 days of implantation.
Bleeding was the most common adverse event 
FIGURE 5 Hemodynamic Monitor Snapshot
In this patient with the fully magnetically levitated LVAS, the arterial pulsatility generated by the device can be seen in the red line (labeled Art). Photo courtesy of the Institute for Clinical and Experimental Medicine, Prague, Czech Republic. LVAS ¼ left ventricular assist system. 
LDH PIHgb
There were no hemolysis events per mean (AE SD) for lactic dehydrogenase (LDH) and plasma hemoglobin (PlHgb) at baseline to month 6. studies (22, 28, 30) . Overall bleeding frequency and need for reoperation due to bleeding in this study is considerably less than reported in prior BTT and DT studies (22, 23, 30, 34) .
Placement of the Full MagLev LVAS in the thorax
eliminates the need to surgically create an abdominal pocket, thereby reducing the amount of surgery required. The wide blood-flow gaps within the rotor, which are 20 times greater than similar devices, might contribute to lower shear stress to minimize hemolysis, platelet activation, and damage to the vWF.
Although vWF preservation was not directly evaluated Values are n (%). *Includes 3 procedural-related events: 1 implant issue (difficulty engaging inflow conduit), 1 following anaphylactic shock from contrast media, and 1 following transcatheter aortic valve implantation procedure. †Seizure (n ¼ 2) and transient ischemic attack (n ¼ 2). ‡Other adverse events include pleural effusion (n ¼ 1), volume status (n ¼ 5), high/low INR (n ¼ 7), and various (n ¼ 10).
in this study, the rate of gastrointestinal bleeding we observed (8%) was lower than the 11% to 25% reported for other devices (28, 34, 35) . Stroke occurs in approximately 7% to 15% of patients undergoing long-term LVAS support (3, 28) .
With an overall lower adverse event rate, particularly bleeding and infection, and the absence of hemolysis and pump thrombosis, the 12% stroke rate (8% debilitating stroke) observed in this study was higher than expected. However, one-half Compared with baseline, patients had improved walk distances at 1, 3, and 6 months. 
